Delivery Order SPE2DB20D2104-SPE2DB25FNAZJ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,639.13 to AmerisourceBergen Drug Corp for Telmisartan-Amlodipine 40-5 mg tablets (30-count supply) on August 27, 2025, with a completion date of August 28, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a single shipment of a combination antihypertensive medication to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Telmisartan-Amlodipine 40-5 mg tablets (30-count) with a ceiling value of $1,234.32 and an ultimate completion date of August 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,108.69 to AmerisourceBergen Drug Corp for the supply of Telmisartan-Amlodipine 40-10mg tablets (30-count) with a completion deadline of September 15, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, placed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Telmisartan-Amlodipine 40-5 mg tablets (30-count) on August 12, 2025, with a ceiling value of $1,344.82 and ultimate completion date of August 13, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and running through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Telmisartan-Amlodipine 40-5 mg tablets (30-count supply) on March 5, 2025, with a ceiling value of $2,115.16. This non-competitive, firm fixed price delivery order is set to be completed by March 6, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply needs. This delivery order falls...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Telmisartan-Amlodipine 40-5 mg tablets in a 30-count package. This competitively awarded, firm fixed-price delivery order has a ceiling value of $3,017.64 and is scheduled for completion by August 13, 2025. The contract is unsolicited for set-aside programs and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp was awarded a delivery order on September 19, 2025, by the Defense Logistics Agency for the supply of Telmisartan-Amlodipine 40-5 mg tablets (30-count) with a ceiling value of $2,273.46. This is a firm fixed-price delivery order with an ultimate completion date of September 22, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on September 9, 2025, valued at $1,227.09 for the supply of Telmisartan-HCTZ 80-12.5 mg tablets in unit dose packages of 30. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of September 10, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $2,833.03 to AmerisourceBergen Drug Corp for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count) on August 1, 2025, with an ultimate completion date of August 4, 2025. This is a firm fixed price, non-set-aside contract performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $5,083.49 to AmerisourceBergen Drug Corp for the supply of Telmisartan-HCTZ 80-12.5 mg tablets in unit dose packaging (30 count) under a firm fixed price contract. This delivery order, which was competitively awarded with no set-aside designation, was executed on July 23, 2025, with an ultimate completion date of July 24, 2025. Performance will take place at the contractor's Corporate Office location in Conshohocken, Pennsylvania....
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNAZJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,501.84 to AmerisourceBergen Drug Corp for the supply of Telmisartan-Amlodipine 80-5 mg tablets in a quantity of 30 units. The contract, awarded on September 19, 2025, with an ultimate completion date of September 22, 2025, operates under firm fixed-price terms with no set-aside designation. Performance will be executed from the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. The IDC serves as the primary mechanism through which AmerisourceBergen provides a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen maintains extensive experience fulfilling competitively awarded federal medical procurement requirements across multiple therapeutic domains, including cardiovascular medications such as this antihypertensive combination product.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 9/19/25 |